All News

vaccination.jpg

Booster Shots for Rheumatology Patients on Immunosuppressive Medications

d ACR Press Release

ATLANTA – The CDC's Advisory Committee on Immunization Practices today recommended that rheumatology patients being actively treated with high-dose corticosteroids, alkylating agents, antimetabolites, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory receive a third dose of the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines.

Read Article
RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
injection-green.jpg

Anakinra's Effects on COVID-19 Outcomes

d Jack Cush, MD

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially highly elevated ferritin and C-reactive prote

Read Article
Osteoarthritis vs. Rheumatoid Arthritis https://t.co/qvVEcKqNAM https://t.co/WDyIZxoL7v

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch Now: The Sentinel Joint: Dr. Kathryn Dao ( @KDAO2011 ) reviews abstract POS0385 presented at the virtual EULAR 2021 meeting. https://t.co/H3DcSHQWHr https://t.co/f7LDNz6oyL

Links:

Dr. John Cush RheumNow ( View Tweet)
Popular on RheumNow https://t.co/BZsl8a6ArW The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/RNFsJadUZx

Links:

Dr. John Cush RheumNow ( View Tweet)
Popular post-- AstraZeneca announced that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the FDA for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. https://t.co/22HVA32IAh https://t.co/CGkBW80un4

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved Xywav - gamma-hydroxybutyrate (GHB) for “idiopathic hypersomnia,” (people sleep 9+hrs/, yet never feel rested). GHB prev approved for narcolepsy https://t.co/38MBpmOAAA https://t.co/5pLLghCYtp

Links:

Dr. John Cush RheumNow ( View Tweet)

A Top Tweet this Week: A large cohort study of rheumatoid arthritis (RA) patients shows that regular tea consumption was associated with a lower risk of RA. https://t.co/ODTs7PdGTN https://t.co/69mi8IlBdj

Links:

Dr. John Cush RheumNow ( View Tweet)
In case you missed it… TB rarely causes arthritis; accounts for 1-5% of all TB (10-30% of pulmonary TB) cases. May present as mono/oligoarthritis, tenosynovitis, dactylitis, Spondylitis (Potts disease), reactive arthritis (Poncets dz) or polyarthritis. https://t.co/RpMrRLQbEa

Links:

Dr. John Cush RheumNow ( View Tweet)

Dont make a point, make a difference - Seth Godin https://t.co/kJE3EGCY83

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Can you manage FM without opioids? Study of 698 Fibromyalgia pts from a tertiary center finds 27.1% taking opioids. Opioid associated with longer Sx duration (>3 yrs), increased age, worse functional impairment & pain catastrophizing https://t.co/N1G4ZtkUE5

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has expanded the use of SHINGRIX vaccine to include adults 18 years and older who are compromised by immunodeficiency or immunosuppression caused by disease or therapy. https://t.co/Wf2mzvOQcU

Links:

Dr. John Cush RheumNow ( View Tweet)

https://t.co/VBxg9fQmt0 Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia... https://t.co/XIB7OVNCvT

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study https://t.co/XVXgEoufCw Nice data another p19 IL23 inhb - safety continues to impress

Links:

Peter Nash drpnash ( View Tweet)

New study data on mRNA vaccines in pts with inflammatory diseases on mostly #TNFi +/- #csDMARDs . ▶️ Effective immune response (lower than healthy controls) ▶️Comparable side effects ▶️ no ⬆️ in DAS28 ▶️ no pts on #Rituximab included https://t.co/aexdFoUzer https://t.co/h1S1S2YsHS

Links:

ARD & RMD Open ARD_BMJ ( View Tweet)
Biomarkers predict early ILD in systemic sclerosis: https://t.co/9z4Swjjy4p we need a biomarker for early disease!

Links:

Peter Nash drpnash ( View Tweet)

Chronologic Progression of Ankylosing Spondylitis https://t.co/ihVVystOMn https://t.co/SXhkkBgzTJ

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID Vaccine Booster Effective for Transplant Recipients in Small Trial For organ transplant recipients, a third dose of Moderna's COVID-19 vaccine more than tripled the proportion with a sufficient antibody response, a randomized trial showed. https://t.co/iD2WFfUP3a https://t.co/eYMdocd9T4

Links:

Dr. John Cush RheumNow ( View Tweet)
A new European real world experience study shows that mepolizumab is effective at both 100 or 300mg every 4 weeks in patients with the rarely encountered eosinophilic granulomatosis with polyangiitis (EGPA; or Churg-Strauss Syndrome). https://t.co/hgeiSHhxSj https://t.co/cfi2nZGzBa

Links:

Dr. John Cush RheumNow ( View Tweet)
×